Providing Incentives, Addressing ‘Stymied Market’ Vital To Stimulating Development Of New Antimicrobials

Washington Post: Letter to the Editor: Developers of antibiotics urgently need government help
Jeffrey Stein, president and chief executive of Cidara Therapeutics and chair of the Antimicrobials Working Group

“While the [editorial, ‘A new superbug threat,’] shone a much-needed spotlight on the growing threat of antimicrobial resistance and highlighted a commercial environment that does not commensurately value the development of potentially lifesaving antibiotics, it overlooked the urgent need to pass legislation that supports the discovery of new antibiotics and addresses the failure of the marketplace to incentivize investment in the development of antimicrobials. … Pending legislation holds promise, but it is unclear when or if any will advance in the current political environment. Cooperation among academia, industry, and bipartisan congressional support is imperative to stimulate innovative antimicrobials. Without adequately addressing the stymied market, necessary innovation for our next ‘miracle drugs’ will come to a rapid stop” (2/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.